Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

An additional application for the test is to detect dysplasia, states Zulueta. There is now evidence that chemo-prevention can be achieved in patients who have dysplasia.

This has been shown in phase II trials, explains Zulueta. Previously, in order to diagnose dysplasia there was an invasive test, however, now the LuCED test can provide a non-invasive diagnosis.

Videos

Dr. Zulueta on the Application of the LuCED Test for Lung Cancer

Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses the LuCED test, a non-invasive tool used to detect early stage lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Low-dose computed tomography (LDCT) screening for lung cancer often leads to follow-up scans for indeterminate nodules. The non-invasive LuCED test may resolve nodule findings and reduce LDCT false positives. When using this test, patient sputum is analyzed by the Cell-CT, which computes 3D images of single cells, allowing measurement of 3D structural biomarkers to identify potentially abnormal cells.

According to Zulueta's findings, the LuCED test demonstrates accurate detection of early stage lung cancer with the potential of detecting pre-cancerous conditions of the lung. These results suggest that suspicious nodules may be efficiently reconciled by this novel tool when used with LDCT.

Javier Zulueta, MD

Articles

Dr. Zulueta on the Application of the LuCED Test for Lung Cancer

Dr. Zulueta on the Non-Invasive LuCED Test for Detection of Early Stage Lung Cancer